RESULTS: Air blast and SSCDS applications were compared using water sensitive paper, bioassays, and pest damage assessments. Pest management and coverage were compared using application volumes of 700 and 795 L ha-1 , respectively. In 2013, adaxial coverage measurements showed no difference between the treatments, but air blast sprayers had higher coverage levels on the abaxial surfaces. There were no significant differences in coverage in 2014. Bioassays using Choristoneura rosaceana fed on leaf discs treated by the SSCDS displayed 95.8% mortality in 2013 and 94.2% mortality in 2014, and air blast treated larval mortality was 95% in 2013 and 100% in 2014. Damage evaluations in both years generally showed no significant differences between the air blast plots and the SSCDS plots, but significant differences between the treated plots and untreated control.
CONCLUSIONS: The prototype SSCDS was an effective pest management tool in high density apples, and offered a number of advantages over an air blast. Further engineering and research into coverage optimization would offer producers a novel tool for foliar agrochemical applications. © 2019 Society of Chemical Industry.
METHODS: A systematic review and meta-analysis was performed in accordance with the PRISMA statement. MEDLINE, EMBASE and Cochrane Library were searched for completed manuscripts until May 2019 on TIA/ischaemic stroke patients, ≥ 18 years, treated with commonly-prescribed antiplatelet therapy, who had platelet function/reactivity testing and prospective follow-up data on recurrent stroke/TIA, myocardial infarction, vascular death or other cerebrovascular outcomes. Data were pooled using random-effects meta-analysis. Primary outcome was the composite risk of recurrent stroke/TIA, myocardial infarction or vascular death. Secondary outcomes were recurrent stroke/TIA, severe stroke (NIHSS > 16) or disability/impairment (modified Rankin scale ≥ 3) during follow-up.
RESULTS: Antiplatelet-HTPR prevalence was 3-65% with aspirin, 8-56% with clopidogrel and 1.8-35% with aspirin-clopidogrel therapy. Twenty studies (4989 patients) were included in our meta-analysis. There was a higher risk of the composite primary outcome (OR 2.93, 95% CI 1.90-4.51) and recurrent ischaemic stroke/TIA (OR 2.43, 95% CI 1.51-3.91) in patients with vs. those without 'antiplatelet-HTPR' on any antiplatelet regimen. These risks were also more than twofold higher in patients with vs. those without 'aspirin-HTPR' and 'dual antiplatelet-HTPR', respectively. Clopidogrel-HTPR status did not significantly predict outcomes, but the number of eligible studies was small. The risk of severe stroke was higher in those with vs. without antiplatelet-HTPR (OR 2.65, 95% CI 1.00-7.01).
DISCUSSION: Antiplatelet-HTPR may predict risks of recurrent vascular events/outcomes in CVD patients. Given the heterogeneity between studies, further prospective, multi-centre studies are warranted.